These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 9292562)

  • 21. 2005 Annual Report: ESRD Clinical Performance Measures Project.
    ; Kinney R
    Am J Kidney Dis; 2006 Oct; 48(4 Suppl 2):S1-106. PubMed ID: 17045862
    [No Abstract]   [Full Text] [Related]  

  • 22. Impact of facility size and profit status on intermediate outcomes in chronic dialysis patients.
    Frankenfield DL; Sugarman JR; Presley RJ; Helgerson SD; Rocco MV
    Am J Kidney Dis; 2000 Aug; 36(2):318-26. PubMed ID: 10922310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemodialysis adequacy in Network 5: disparity between states and the role of center effects.
    Fink JC; Armistead N; Turner M; Gardner J; Light P
    Am J Kidney Dis; 1999 Jan; 33(1):97-104. PubMed ID: 9915273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adequacy of hemodialysis.
    Hakim RM; Depner TA; Parker TF
    Am J Kidney Dis; 1992 Aug; 20(2):107-23. PubMed ID: 1496963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Kt/V and urea reduction ratio in measuring dialysis adequacy in paediatric haemodialysis in England.
    Dunne N; Campbell M; Fitzpatrick M; Callery P
    J Ren Care; 2014 Jun; 40(2):117-24. PubMed ID: 24646007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variation in infection prevention practices in dialysis facilities: results from the national opportunity to improve infection control in ESRD (End-Stage Renal Disease) project.
    Chenoweth CE; Hines SC; Hall KK; Saran R; Kalbfleisch JD; Spencer T; Frank KM; Carlson D; Deane J; Roys E; Scholz N; Parrotte C; Messana JM
    Infect Control Hosp Epidemiol; 2015 Jul; 36(7):802-6. PubMed ID: 25773538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A data-driven approach to improving the care of in-center hemodialysis patients.
    McClellan WM; Frederick PR; Helgerson SD; Hayes RP; Ballard DJ; McMullan M
    Health Care Financ Rev; 1995; 16(4):129-40. PubMed ID: 10151884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cycler adequacy and prescription data in a national cohort sample: the 1997 core indicators report. Health Care Financing Administration Peritoneal Dialysis Core Indicators Study Group.
    Rocco MV; Flanigan MJ; Prowant B; Frederick P; Frankenfield DL
    Kidney Int; 1999 May; 55(5):2030-9. PubMed ID: 10231468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.
    McClellan WM; Frankenfield DL; Wish JB; Rocco MV; Johnson CA; Owen WF;
    Am J Kidney Dis; 2001 May; 37(5):E36. PubMed ID: 11325701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pilot study of state surveying methods for ESRD facilities.
    Diamond L; Armistead N; Horansky C
    Nephrol News Issues; 1991 Jun; 5(6):43-4, 49-52. PubMed ID: 1961303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dialysis outcome quality initiative (DOQI) guideline for hemodialysis adequacy.
    Di Giulio S; Meschini L; Triolo G
    Int J Artif Organs; 1998 Nov; 21(11):757-61. PubMed ID: 9894756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adequacy of dialysis and differences in hematocrit among dialysis facilities.
    Ifudu O; Uribarri J; Rajwani I; Vlacich V; Reydel K; Delosreyes G; Friedman EA
    Am J Kidney Dis; 2000 Dec; 36(6):1166-74. PubMed ID: 11096041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of care for patients with chronic kidney disease in the United States: dying for improvement.
    Owen WF
    J Am Soc Nephrol; 2003 Jul; 14(7 Suppl 2):S76-80. PubMed ID: 12819307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving the care of ESRD patients: a success story.
    McClellan WM; Frankenfield DL; Frederick PR; Helgerson SD; Wish JB; Sugarman JR
    Health Care Financ Rev; 2003; 24(4):89-100. PubMed ID: 14628402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rebound kinetics of beta2-microglobulin after hemodialysis.
    Leypoldt JK; Cheung AK; Deeter RB
    Kidney Int; 1999 Oct; 56(4):1571-7. PubMed ID: 10504510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The dilemmas of patient treatment for end-stage renal disease.
    Schmidt RW; Blumenkrantz M; Wiegmann TB
    Am J Kidney Dis; 1983 Jul; 3(1):37-47. PubMed ID: 6346866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First hemodialysis access selection varies with patient acuity.
    Friedman AL; Walworth C; Meehan C; Wander H; Shemin D; DeSoi W; Kitsen J; Hill C; Lambert C; Mesler D
    Adv Ren Replace Ther; 2000 Oct; 7(4 Suppl 1):S4-10. PubMed ID: 11053581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of non-response to the In-Center Hemodialysis Consumer Assessment of Healthcare Providers and Systems (ICH CAHPS) survey.
    Dad T; Tighiouart H; Fenton JJ; Lacson E; Meyer KB; Miskulin DC; Weiner DE; Richardson MM
    BMC Health Serv Res; 2018 Oct; 18(1):790. PubMed ID: 30340585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double target comparison of blood-side methods for measuring the hemodialysis dose.
    Prado M; Roa LM; Palma A; Milán JA
    Kidney Int; 2005 Dec; 68(6):2863-76. PubMed ID: 16316364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.